Alzamend Neuro Inc (ALZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) has a cash flow conversion efficiency ratio of -0.795x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.74 Million) by net assets ($2.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALZN net asset quality score to measure how much of total assets are equity-financed.
Alzamend Neuro Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ALZN cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Alzamend Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alzamend Neuro Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
McBride plc
LSE:MCB
|
0.393x |
|
Sherpa II Holdings Corp
V:SHRP
|
-0.016x |
|
H&T Group plc
LSE:HAT
|
0.033x |
|
Tenon Medical Inc
NASDAQ:TNON
|
-1.562x |
|
Shamaym Improve Ltd
TA:SHMM
|
1.183x |
|
NORTHSTAR GOLD CORP.
F:3WV
|
-0.118x |
|
Century Global Commodities Corp
TO:CNT
|
-0.047x |
|
Americore Resources Corp.
V:AMCO
|
-0.236x |
Annual Cash Flow Conversion Efficiency for Alzamend Neuro Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Alzamend Neuro Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see ALZN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $3.97 Million | $-6.57 Million | -1.655x | -151.92% |
| 2024-04-30 | $-2.59 Million | $-8.27 Million | 3.188x | +208.80% |
| 2023-04-30 | $3.05 Million | $-8.92 Million | -2.930x | -491.46% |
| 2022-04-30 | $13.35 Million | $-6.61 Million | -0.495x | +63.23% |
| 2021-04-30 | $2.01 Million | $-2.71 Million | -1.347x | +52.81% |
| 2020-04-30 | $821.71K | $-2.35 Million | -2.855x | +13.44% |
| 2019-04-30 | $316.92K | $-1.05 Million | -3.298x | -272.82% |
| 2018-04-30 | $2.32 Million | $-2.05 Million | -0.885x | -136.52% |
| 2017-04-30 | $-584.93K | $-1.42 Million | 2.422x | -98.61% |
| 2016-04-30 | $-106.00 | $-18.49K | 174.453x | -- |
About Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more